XYLOBIOSE

CAS No. 6860-47-5

XYLOBIOSE( —— )

Catalog No. M20482 CAS No. 6860-47-5

XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 46 In Stock
5MG 46 In Stock
10MG 77 In Stock
25MG 126 In Stock
50MG 184 In Stock
100MG 272 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    XYLOBIOSE
  • Note
    Research use only, not for human use.
  • Brief Description
    XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.
  • Description
    XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF-α|IL-1β
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6860-47-5
  • Formula Weight
    282.24
  • Molecular Formula
    C10H18O9?
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 250 mg/mL (885.77 mM)
  • SMILES
    O[C@@H]1CO[C@@H](O[C@@H]2COC(O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O
  • Chemical Name
    D-Xylose 4-O-beta-D-xylopyranosyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Soo-Min L Eunju K Jae-Ho S et al. Xylobiose Prevents High-Fat Diet Induced Mice Obesity by Suppressing Mesenteric Fat Deposition and Metabolic Dysregulation[J]. Molecules 2018 23(3):705-.
molnova catalog
related products
  • INH1

    INH1 is a cell-permeable Hec1 inhibitor that specifically disrupts the Hec1/Nek2 interaction.

  • Ragifilimab

    Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.

  • UCB-9260

    UCB-9260 inhibits TNF signaling by stabilizing an asymmetric form of the trimer.